FENTON DENNIS M 4

What Happened Dennis M. Fenton, a director of First Tracks Biotherapeutics, was granted two equity awards on May 12, 2026: 15,000 restricted stock units (RSUs) and a derivative award covering 42,000 shares (reported as a zero-price acquisition). The reported acquisition price is $0.00, so the filing shows $0 cash outlay at grant; these are compensation-style awards rather than open-market purchases or sales.

Key Details

• Transaction date: May 12, 2026; Form 4 filed May 14, 2026 (timely filing).
• Grant details: 15,000 RSUs and an award/option for 42,000 shares; reported price $0.00 (derivative awards).
• Vesting: RSUs vest 100% on the issuer’s 2027 annual meeting of shareholders, subject to continued service. The 42,000-option award vests 1/12 monthly beginning June 12, 2026 until fully vested, subject to service.
• Additional holdings: Reporting person also holds options to purchase up to an aggregate of 97,827 additional shares (per filing footnote).
• Shares owned after the transaction: not specified in this filing.
• Type: Award/Grant (code A) — compensation, not a purchase or sale.

Context These entries are compensation grants to a director. RSUs convert into common shares for no additional payment when they settle; the option-style award will vest monthly per the schedule above. Such grants are routine for executive/director compensation and do not by themselves signal buying or selling activity in the open market.